Savara Inc.
SVRA · Nasdaq · USD · Market cap $953M · 70 employees
Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases in the United States.
FAIL · Does not pass the screenPrice as of 20 Nov 2026Daily close, not a live quote
Screened 2026-11-20 · the tape above runs as of 12:17 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed
Key facts today
- Price4.26 USD at the 20 Nov 2026 close
- Fair valueUnder review: our model's value is 2.17x the price, above our 2.00x limit.
- Our regime readMarkup, as of 15 Nov 2026
- Ethical screenDoes not pass
- OptionsOpen interest leans slightly to calls (put/call 0.97)
- Last reviewed20 Nov 2026 (1 day ago)
- Release timesRelease and earnings times on your chart: Event Guard Mentor
A summary of the dated readings below, not a live quote and not advice.
Our fair-value range: range not available (screen dated 2026-11-20).
- Trend Markup
- Insiders no filings inside 60 days, left as found
- Positioning no disclosures inside 60 days, left as found
- Options put/call open interest 0.97, read 2026-11-19
- Ethical does not pass the values gate
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
This name holds its markup label.
Savara Inc. holds its Markup at $4.26. Consolidating, no directional conviction, held for 245 days.
| Phase | Markup |
| Quantitative state | Consolidating, no directional conviction, held for 245 days |
| Price at the screen | $4.26 |
| Valuation | N/A trailing · -14.90 forward price to earnings |
| Values screen | FAIL · score 70.0 |
| Beta | 0.20 |
Five Screens: SVRA's Results
FAIL. Interest-bearing securities
| Test | Figure | Limit | Status |
|---|---|---|---|
| Business activity | Permissible | Permissible core business | Pass |
| Debt load | 11.80% | Below 33% | Pass |
| Interest-bearing cash | 79.91% | Below 33% | Fail |
| Receivables | 13.59% | Below 49% | Pass |
Definitions, sources and threshold rules: ticker values-screen methodology.
The Ethical ReadWhy It Falls Short, in Plain English
Savara's business is fine, but its cash and interest-bearing securities are about 80% of its assets, well over the ~33% line, so it does not pass on the financial screens.
Read as at 20 Nov 2026. It updates when the underlying figures move, and past reads are kept below. How we screen.
Follow this verdict
Get an email when SVRA's ethical verdict changes
Today SVRA does not pass the screen. If new figures move it to a pass, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
The Fair Value Range
Fair value under review. Our model's value is 2.17x the price, above our 2.00x limit. We show no fair value, margin of safety or value read built on it until the review clears.
The Street's RangeStreet. Average target +141%.
| Forward P/E | -14.9x |
| EPS, trailing | -0.58 |
| EPS, forward | -0.31 |
| Profit margin | 0.0%currently unprofitable |
| Return on equity | -105.5%not currently earning a positive return on equity |
| FCF yield | -6.00% |
| Debt to equity | 0.21minimal debt: a conservative balance sheet |
| Current ratio | 10.13comfortably covers its short-term bills |
| Beta | 0.20barely tracks the market's swings |
| Short interest, float | 0.25% |
| 52-week range | 3.34 - 7.01 |
| Market cap | $953M |
| Employees | 70 |
SVRA-specific watchpoints · The things to watch: it's a small-cap, so the share price can swing harder than the market; as a biotechnology name, trial and regulatory outcomes can move it sharply either way.
Metric definitions and interpretation rules: ticker-page methodology.
Every Entry, As Written
The framework has shifted from distribution to markup since the last review.
The framework has shifted from markup to distribution since the last review.
The framework has shifted from distribution to markup since the last review.
The framework has shifted from markdown to distribution since the last review. Earnings landed in this window. Ethical screening: FAIL.
Written on its date, before the outcome; never pruned.
- Here's Why You Should Add Savara Stock to Your Portfolio Now Zacks · 22 Jul 2026
- What Savara Investors Should Know About This 580,187-Option Exercise and FDA Timeline Motley Fool · 27 Jun 2026
- Assessing Savara (SVRA) Valuation As Shares Cool After Strong Long Term Returns Simply Wall St. · 8 Jun 2026
- Savara Inc. (SVRA) Reports Q1 Financial Results Insider Monkey · 22 May 2026
- Assessing Savara (SVRA) Valuation After FDA Extends Priority Review For Molgramostim Simply Wall St. · 26 Apr 2026
Headlines from third-party outlets, linked for reference: not our reporting, not advice.
Screened names in the same industry · explore each on its own page.
| Period | Price then | Price return | Divs per share | $1,000 became | Total return |
|---|---|---|---|---|---|
| 1 month | $5.12 | -0.6% | · | $994 | -0.6% |
| 2 months | $5.66 | -10.1% | · | $899 | -10.1% |
| 3 months | $5.32 | -4.3% | · | $957 | -4.3% |
| 6 months | $6.94 | -26.7% | · | $733 | -26.7% |
| 1 year | $2.33 | +118.5% | · | $2,185 | +118.5% |
| 2 years | $4.17 | +22.1% | · | $1,221 | +22.1% |
| 3 years | $3.23 | +57.6% | · | $1,576 | +57.6% |
| 5 years | $1.83 | +178.1% | · | $2,781 | +178.1% |
Historical returns from market close data. Past performance does not guarantee future results.
This entry now belongs to the ledger. Whatever SVRA does next, these words stay.
Thirteen thousand names carry this page. One desk keeps them honest.
Membership opens the full screen archive, the composites built from it, and the daily coverage that prices what the screen approves.
Join the deskScreening is research, not a fatwa and not financial advice. Figures are drawn from public accounts at the screen date shown. Always manage your risk.